Veeva Systems (VEEV) Resumen de Acciones
Veeva Systems Inc. ofrece software basado en la nube para la industria de las ciencias de la vida en Norteamérica, Europa, Asia-Pacífico, Oriente Medio, África y Latinoamérica. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 5/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en VEEV a partir de nuestros controles de riesgos.
VEEV Community Fair Values
Create NarrativeSee what 247 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$320
FV
36.3% infravalorado descuento intrínseco18.51%
Revenue growth p.a.
2.3k
users have viewed this narrative6users have liked this narrative
0users have commented on this narrative
40users have followed this narrative
Competidores de Veeva Systems Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$203.78 |
| Máximo en las últimas 52 semanas | US$310.50 |
| Mínimo de 52 semanas | US$148.05 |
| Beta | 0.94 |
| Cambio en 1 mes | 10.62% |
| Variación en 3 meses | 18.75% |
| Cambio de 1 año | -27.57% |
| Variación en 3 años | 3.48% |
| Variación en 5 años | -39.86% |
| Variación desde la OPV | 448.39% |
Noticias y actualizaciones recientes
Seeking Alpha • Jul 24
Veeva Systems: Steady Execution, Attractive P/E Multiples
Summary Veeva Systems stands out as a compelling buy amid a potential market rotation into lagging software stocks. VEEV benefits from a highly regulated customer base, strong growth and margin profile, and robust sales execution. After a near-20% YTD decline and recent post-earnings volatility, VEEV's valuation is now especially attractive. I reiterate a buy rating, citing a healthy balance sheet with $7.31B cash and no debt, and favorable enterprise value. Read the full article on Seeking Alpha
Actualización de narrativa • Jul 13
VEEV: AI Disruption Fears Will Pressure Core CRM Durability
Veeva Systems' updated analyst price target has been reduced from about $232.80 to $165.00. Analysts cite slightly lower modeled revenue growth, a lower assumed future P/E multiple, and ongoing debates around AI disruption and competitive pressure in core CRM offerings, despite steady Q1 execution and continued AI product development.
Nueva narrativa • Jul 03
AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability
Investors often look for artificial intelligence winners in the obvious places: semiconductors, hyperscalers, and general-purpose software platforms. But some of the most durable AI opportunities may sit in far less glamorous places—inside the regulated workflows where a mistake is not merely inconvenient, but potentially delays a drug trial, a regulatory submission, or a therapy reaching patients.
Actualización de narrativa • Jun 29
VEEV: AI Execution And CRM Wins Will Drive Future Upside
Veeva Systems’ analyst fair value estimate has been reset lower from about $380 to roughly $338, reflecting Street price target cuts as analysts weigh solid Q1 execution against AI disruption risk, competitive CRM questions, and a shift toward more measured profit margin and P/E assumptions. Analyst Commentary Street research on Veeva Systems presents a mixed but generally constructive picture, with many firms recalibrating price targets while still pointing to solid Q1 execution, ongoing demand in health technology, and emerging AI and CRM catalysts as key elements in their valuation work.Recent updates
Seeking Alpha • Jul 24
Veeva Systems: Steady Execution, Attractive P/E Multiples
Summary Veeva Systems stands out as a compelling buy amid a potential market rotation into lagging software stocks. VEEV benefits from a highly regulated customer base, strong growth and margin profile, and robust sales execution. After a near-20% YTD decline and recent post-earnings volatility, VEEV's valuation is now especially attractive. I reiterate a buy rating, citing a healthy balance sheet with $7.31B cash and no debt, and favorable enterprise value. Read the full article on Seeking AlphaActualización de narrativa • Jul 13
VEEV: AI Disruption Fears Will Pressure Core CRM Durability
Veeva Systems' updated analyst price target has been reduced from about $232.80 to $165.00. Analysts cite slightly lower modeled revenue growth, a lower assumed future P/E multiple, and ongoing debates around AI disruption and competitive pressure in core CRM offerings, despite steady Q1 execution and continued AI product development.Nueva narrativa • Jul 03
AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability
Investors often look for artificial intelligence winners in the obvious places: semiconductors, hyperscalers, and general-purpose software platforms. But some of the most durable AI opportunities may sit in far less glamorous places—inside the regulated workflows where a mistake is not merely inconvenient, but potentially delays a drug trial, a regulatory submission, or a therapy reaching patients.Actualización de narrativa • Jun 29
VEEV: AI Execution And CRM Wins Will Drive Future Upside
Veeva Systems’ analyst fair value estimate has been reset lower from about $380 to roughly $338, reflecting Street price target cuts as analysts weigh solid Q1 execution against AI disruption risk, competitive CRM questions, and a shift toward more measured profit margin and P/E assumptions. Analyst Commentary Street research on Veeva Systems presents a mixed but generally constructive picture, with many firms recalibrating price targets while still pointing to solid Q1 execution, ongoing demand in health technology, and emerging AI and CRM catalysts as key elements in their valuation work.Artículo de análisis • Jun 20
Veeva Systems (VEEV) Stock Could Be 38% Undervalued After Fed Driven Pullback
Veeva Systems (VEEV) shares fell after the Federal Reserve held its benchmark rate and signaled a more restrictive stance, as higher Treasury yields weighed on software sector valuations, including healthcare and life sciences platforms. See our latest analysis for Veeva Systems. At around US$153.30, Veeva Systems’ recent share price weakness has been broad based, with a 1 day share price return of 1% and a year to date share price return down 30.16%, while the 1 year total shareholder return...
Actualización de narrativa • Jun 15
VEEV: AI Execution And CRM Wins Will Support Future Multiple Reacceleration
Narrative Update The analyst price target for Veeva Systems in this framework is updated from about $263 to about $245, as analysts balance solid Q1 execution and raised guidance with AI disruption risk, CRM competition from Salesforce, and questions around the quality and mix of recent upside, particularly in services. Analyst Commentary Recent research on Veeva Systems reflects a split view, with most analysts acknowledging solid Q1 execution and raised guidance, but debating how much weight to give AI disruption risk, CRM competition, and the quality of services driven upside when thinking about valuation, execution, and long term growth.Actualización de narrativa • Jun 01
VEEV: AI Moat And CRM Commitments Will Support Future Multiple Reacceleration
Narrative Update The analyst price target for Veeva Systems has been trimmed by about $2 to $262.68 as analysts factor in compressed software multiples, while largely maintaining their underlying growth, margin, and P/E assumptions. Analyst Commentary Recent research on Veeva Systems clusters around strong reported execution in Q4, tempered by valuation resets tied to compressed software multiples and longer term questions around AI and CRM competition.Actualización de narrativa • May 11
VEEV: AI Moat And CRM Commitments Will Support Premium Multiple
Veeva Systems' updated analyst price target edges lower to about $264 from roughly $265, as analysts keep their broadly positive take on the company's recent Q4 results but adjust valuation assumptions to reflect compressed software multiples and ongoing debates around AI, R&D growth, and CRM stability. Analyst Commentary Recent research on Veeva reflects a mix of optimism about execution in Q4 and caution around valuation and longer term growth drivers.Actualización de narrativa • Apr 25
VEEV: AI Moat And Subscription Resilience Will Support Premium Multiple
Analysts have trimmed the Veeva Systems price target slightly, with the model fair value moving from about $270.93 to $264.46, as modestly lower assumed future P/E multiples more than offset largely unchanged growth and margin expectations. Analyst Commentary Recent Street research around Veeva Systems shows a split view, with many firms trimming price targets while still pointing to solid execution and specific areas of uncertainty that could influence the valuation over time.Actualización de narrativa • Apr 08
VEEV: AI And Subscription Resilience Will Support Premium Software Multiple
Analysts trimmed the blended Veeva Systems price target by aligning with sector wide software multiple compression, even as they point to strong Q4 execution, resilient subscription growth, and an emerging AI and product pipeline as key longer term supports. Analyst Commentary Recent Street research around Veeva Systems reflects a mix of optimism on execution and growth, alongside more cautious views on competitive risk, AI impact, and valuation.Actualización de narrativa • Mar 25
VEEV: AI Adoption In R&D Workflows Will Support Durable Premium Outlook
Analysts have adjusted their price targets on Veeva Systems into a roughly $190 to $317 range, generally trimming prior targets by tens of dollars as software valuation multiples compress, even after what they describe as solid Q4 results and broadly constructive longer term fundamentals. Analyst Commentary Recent research paints a mixed but generally constructive picture for Veeva Systems, with most firms trimming price targets while still pointing to solid execution and durable fundamentals.Actualización de narrativa • Mar 11
VEEV: AI Adoption And CRM Commitments Will Support Durable Premium Outlook
We are trimming our Veeva Systems fair value estimate to $270.93 from $302.60, as analysts broadly reset price targets in response to sector wide software multiple compression and slightly more measured assumptions for revenue growth, margins, and future P/E multiples, despite generally solid Q4 results and guidance. Analyst Commentary Street research on Veeva Systems has become more mixed, with many firms cutting price targets while still acknowledging solid Q4 execution and robust profitability.Actualización de narrativa • Feb 25
VEEV: AI Execution And CRM Stability Will Support Durable Premium Outlook
Our fair value estimate for Veeva Systems has edged down from $308.63 to $302.60. This reflects a series of reduced Street price targets as analysts weigh maturing products, competitive pressures, software sentiment, and the balance of growth opportunities against current valuation.Actualización de narrativa • Feb 10
VEEV: Roche Commitment And CRM Retention Will Support Durable Premium Outlook
Our analyst fair value estimate for Veeva Systems has been trimmed slightly to $308.63. This reflects a modest reset in Street price targets as analysts balance concerns about slower growth in maturing products and competitive pressure with ongoing strengths in areas like Crossix, AI adoption, and large CRM wins such as Roche.Nueva narrativa • Jan 28
Rising Life Sciences Cloud Standardization And AI Adoption Will Support Strong Long Term Upside
Catalysts About Veeva Systems Veeva Systems provides cloud based software, data and consulting services to life sciences companies across commercial, R&D and manufacturing functions. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Jan 27
VEEV: Roche Rollout And CRM Retention Will Support Durable Premium Outlook
The analyst price target embedded in our Veeva Systems model edges slightly lower to about US$310 from roughly US$311. This reflects a blend of more cautious views on growth and competitive pressure, along with offsetting positive views on durable margins, CRM customer retention, and newer areas such as Crossix and early AI traction.Actualización de narrativa • Jan 12
VEEV: Roche Expansion And CRM Migrations Will Support Durable Premium Outlook
Analysts have trimmed their fair value estimate for Veeva Systems by about US$1 to US$310.98, reflecting modest adjustments to discount rate and growth assumptions while still pointing to what they see as durable growth drivers such as pharma CRM migrations, broader Vault adoption and newer areas like Crossix and AI. Analyst Commentary Recent Street research on Veeva Systems reflects a mix of optimism and caution, with differing views clustering around the durability of growth in CRM and Vault, the timing of pharma migrations, and how current valuation stacks up against execution and contract wins.Actualización de narrativa • Dec 19
VEEV: Roche Commitment And CRM Migrations Will Likely Sustain Premium Outlook
Analysts have modestly trimmed their blended price target for Veeva Systems to about $312 from roughly $321, reflecting a slightly higher discount rate and lower implied future multiple, even as they highlight accelerating CRM migrations, including Roche's global Vault CRM rollout, and improving long term growth and margin expectations. Analyst Commentary Street research remains broadly constructive on Veeva Systems, with recent target changes reflecting a recalibration of software multiples rather than a material shift in company specific fundamentals.Artículo de análisis • Dec 03
Veeva Systems' (NYSE:VEEV) Performance Is Even Better Than Its Earnings Suggest
Investors were underwhelmed by the solid earnings posted by Veeva Systems Inc. ( NYSE:VEEV ) recently. We have done...Actualización de narrativa • Nov 11
VEEV: Continued Momentum And New Commitments Will Likely Sustain Premium Outlook
Analysts have significantly raised their price targets on Veeva Systems, with recent updates moving targets as high as $380. They cite the company's strong sales growth prospects and solid momentum, driven by accelerating CRM customer commitments and new partnerships.Actualización de narrativa • Oct 27
Pharma Wins And New Partnerships Will Drive Cloud Momentum In Coming Quarters
Veeva Systems' analyst price target saw a significant increase, rising by more than $80 to reflect higher expectations for sales growth and ongoing customer commitments. Analysts cited the company’s strengthening position in CRM and positive momentum across key pharma relationships.Actualización de narrativa • Oct 13
IQVIA Resolution And Embedded AI Will Expand Digital Healthcare Cloud
Narrative Update on Veeva Systems: Analyst Price Target Revision Analysts have raised their fair value estimate for Veeva Systems to approximately $321 per share, up by nearly $4. They cited stronger than expected sales momentum, driven by new major customer commitments and continued growth in key business segments.Actualización de narrativa • Aug 29
Data Cloud Expansion And AI Efficiencies Will Drive Future Success
Analysts have raised their price target for Veeva Systems to $314.71, citing strong Q2 “beat and raise” results, momentum in both Commercial and R&D segments, successful Vault CRM rollouts with major pharma clients, and ongoing market share gains in life sciences CRM. Analyst Commentary Bullish analysts highlighted Veeva's strong “beat and raise” Q2 results, with both subscription and services revenues growing solidly year-over-year, driven by performance in both Commercial and R&D technology segments.Seeking Alpha • Apr 17
Veeva Systems: Substantially Overvalued As Growth Slows
Summary Veeva Systems is overvalued, trading at frothy levels despite only ~10% growth, and facing a potential slowdown in 2025; I recommend a sell rating. The company excels in the life sciences vertical with unique solutions but its ambitious revenue targets (doubling revenue by 2030) may be tough to achieve organically. Valuation multiples are high at ~10 EV/FY26 revenue and ~30x FY26 P/E, well above a number of peers - some of which are growing even faster than Veeva. Read the full article on Seeking AlphaSeeking Alpha • Mar 19
Veeva Systems: Staying Buy Rated As VEEV Is Executing Well
Summary I reaffirm my buy rating on Veeva Systems due to strong 4Q25 results, driven by R&D growth and positive Vault CRM adoption traction. VEEV's revenue grew 14% y/y to $721 million, beating expectations, with significant margin improvements and a strong balance sheet. Vault CRM added 20 new customers, with multiple top 20 pharma commitments expected in 2025, signaling positive transition progress. Data Cloud segment shows strong momentum, with new initiatives like Pulse expected to drive further CRM adoption and growth. Read the full article on Seeking AlphaSeeking Alpha • Mar 07
Veeva Systems: Solid Q4 With Margin Expansion
Summary I reiterate my “Strong Buy” rating on Veeva Systems Inc. with a one-year target price of $275 per share due to strong CRM migration and margin improvement. Veeva reported 14.3% revenue growth and 28.7% adjusted operating profit growth, driven by robust CRM adoption and billing growth. Management's guidance for FY26 includes $3.04-$3.055 billion in revenue, with anticipated 12% revenue growth despite high-interest rate challenges. I foresee continued margin expansion and revenue growth recovery to 16% by FY27 for VEEV, supported by CRM migration and easing capital funding challenges. Read the full article on Seeking AlphaSeeking Alpha • Jan 28
Veeva Systems: Forget The Short-Term Volatility; The Long Term Is Promising
Summary I rate Veeva Systems as a 'Buy' due to its strong performance recovery, despite competition from Salesforce and industry uncertainties under Trump's administration. VEEV's migration to its own CRM, Veeva Vault, is a long-term tailwind, enhancing its ecosystem and competitive edge. The Company's Q3 2025 results exceeded expectations, with significant revenue, net income, and free cash flow growth, raising FY 2025 guidance. Despite short-term volatility, Veeva's specialization in life sciences, strong balance sheet, and innovative culture position it well for long-term growth. Read the full article on Seeking AlphaRentabilidad de los accionistas
| VEEV | US Healthcare Services | Mercado US | |
|---|---|---|---|
| 7D | 9.4% | 6.4% | 0.5% |
| 1Y | -27.6% | -35.4% | 16.5% |
Rentabilidad vs. Industria: VEEV superó a la industria US Healthcare Services, que obtuvo un rendimiento del -35.4% el año pasado.
Rentabilidad vs. Mercado: VEEV obtuvo unos resultados inferiores a los del mercado US, que fueron del 16.5% el año pasado.
Volatilidad de los precios
| VEEV volatility | |
|---|---|
| VEEV Average Weekly Movement | 7.0% |
| Healthcare Services Industry Average Movement | 9.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: VEEV no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de VEEV (7%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2007 | 7,928 | Peter Gassner | www.veeva.com |
Veeva Systems Inc. proporciona software basado en la nube para la industria de las ciencias de la vida en Norteamérica, Europa, Asia-Pacífico, Oriente Medio, África y Latinoamérica. La empresa ofrece Veeva Commercial Cloud, que comprende Veeva Vault CRM Suite para empresas farmacéuticas y biotecnológicas; Veeva Medical, que proporciona una fuente de contenido médico a través de múltiples canales y geografías; Veeva PromoMats, una solución integral de gestión de contenidos y activos digitales; y Veeva Crossix, una plataforma de análisis para marcas farmacéuticas. También proporciona Veeva Data Cloud, como Veeva OpenData, una solución de datos de referencia de clientes; Veeva Link, que proporciona datos profundos; Veeva Compass, que incluye datos de pacientes longitudinales y desidentificados; y Veeva CRM Pulse que proporciona acceso y métricas de compromiso multicanal.
Resumen de fundamentos de Veeva Systems Inc.
| Estadísticas fundamentales de VEEV | |
|---|---|
| Capitalización bursátil | US$32.74b |
| Beneficios(TTM) | US$941.65m |
| Ingresos (TTM) | US$3.32b |
35.2x
Ratio precio-beneficio (PE)10.0x
Ratio precio-ventas (PS)¿Está VEEV sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de VEEV | |
|---|---|
| Ingresos | US$3.32b |
| Coste de los ingresos | US$829.12m |
| Beneficio bruto | US$2.49b |
| Otros gastos | US$1.55b |
| Beneficios | US$941.65m |
Últimos beneficios comunicados
Apr 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 5.80 |
| Margen bruto | 75.02% |
| Margen de beneficio neto | 28.37% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado VEEV a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/31 03:34 |
| Precio de las acciones al final del día | 2026/07/31 00:00 |
| Beneficios | 2026/04/30 |
| Ingresos anuales | 2026/01/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Veeva Systems Inc. está cubierta por 44 analistas. 29 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Joseph Vruwink | Baird |
| Saket Kalia | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |